KMTS
HealthcareKestra Medical Technologies, Ltd. · Medical - Instruments & Supplies · $1B
What is Kestra Medical Technologies, Ltd.?
Kestra Medical Technologies is a small-cap wearable medical device company focused on cardiovascular disease. Based in Kirkland, Washington, it develops connected monitoring and therapeutic technologies aimed at reducing sudden cardiac arrest risk.
Kestra generates revenue by developing and commercializing its Cardiac Recovery System platform — a unified solution that combines wearable cardioverter defibrillator technology, digital health tools, and patient support services. Its flagship product, the ASSURE WCD, is worn by patients at elevated risk of sudden cardiac arrest. The platform also includes integrated digital solutions designed to improve engagement between patients and healthcare providers, with the goal of enhancing clinical outcomes across the cardiovascular care continuum.
Kestra Medical Technologies was founded in 2014 and is headquartered in Kirkland, Washington.
- ASSURE WCD — wearable cardioverter defibrillator for sudden cardiac arrest protection
- Cardiac Recovery System — unified monitoring and therapeutic platform
- Integrated digital health tools for patient and provider engagement
- Remote patient oversight and support services
Is KMTS a Good Stock to Buy?
UQS Score rates KMTS as Poor overall, reflecting meaningful challenges across several fundamental dimensions.
The brightest spot in Kestra's profile is its Growth pillar, rated Good — suggesting the company is expanding its commercial footprint in the wearable cardiac device market. The Risk pillar comes in at Neutral, indicating the risk profile is neither unusually high nor particularly low relative to sector peers.
Both the Quality and Moat pillars are rated Weak, pointing to limited competitive durability and below-average business fundamentals. The Valuation pillar is Elevated, meaning the market is pricing in significant future execution that has yet to materialize.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does KMTS pay dividends?
No — Kestra Medical Technologies, Ltd. does not currently pay a dividend.
KMTS does not currently pay a dividend. For an early-stage commercial medical device company like Kestra, this is typical — available capital is directed toward product development, sales force expansion, and building out its digital health infrastructure rather than returning cash to shareholders.
When does KMTS report earnings?
Kestra Medical Technologies reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
As a growth-stage medical device company, Kestra's quarterly results tend to reflect the pace of commercial adoption for the ASSURE WCD platform. Revenue trajectory and operating expense trends are the key metrics investors typically monitor each quarter.
For the most recent quarter's results and guidance, visit Kestra Medical Technologies' investor relations page directly.
KMTS Price History
-6.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Kestra Medical Technologies, Ltd.?
Based on Kestra Medical Technologies, Ltd.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
KMTS Long-term Outlook
Kestra's Good Growth pillar suggests the company is on an upward commercial trajectory, driven by increasing adoption of its wearable cardiac device platform. However, the Weak Quality and Moat pillars temper the long-term outlook — the business has not yet demonstrated durable competitive advantages or strong underlying unit economics. The Elevated Valuation pillar adds further caution, as the current market price appears to reflect optimistic future scenarios. Execution risk remains a central consideration for investors evaluating this name.
Growth drivers
- Expanding adoption of the ASSURE WCD among at-risk cardiac patients
- Growth in integrated digital health and remote monitoring services
- Increasing awareness and clinical use of wearable cardioverter defibrillators
Key risks
- Weak moat leaves the platform vulnerable to competition from larger device makers
- Elevated valuation leaves little margin for execution shortfalls
- Reimbursement and regulatory dynamics in the wearable cardiac device market
KMTS vs Peers
Kestra competes within the broader medical device and digital health landscape alongside companies focused on therapeutic and monitoring technologies.
NovoCure applies electric field therapy to oncology rather than cardiac care, representing a distinct therapeutic modality and patient population.
STAAR Surgical focuses on implantable lens technology for vision correction, operating in a different clinical category with a more established commercial model.
AtriCure targets atrial fibrillation through surgical ablation systems, sharing the cardiovascular focus but competing through hospital-based surgical channels rather than wearable devices.
Frequently Asked Questions
What does Kestra Medical Technologies do?
Kestra Medical Technologies develops wearable medical devices and digital health solutions for patients at risk of sudden cardiac arrest. Its core product, the ASSURE WCD, is a wearable cardioverter defibrillator that monitors patients and delivers therapy if needed. The broader Cardiac Recovery System platform integrates monitoring, treatment, and digital support services into a single connected solution.
Does KMTS pay dividends?
No, KMTS does not currently pay a dividend. As a growth-stage company investing heavily in commercializing its cardiac device platform, Kestra reinvests available capital into operations rather than distributing it to shareholders. Income-focused investors should factor this into their evaluation.
When does KMTS report earnings?
Kestra Medical Technologies reports financial results on a quarterly basis, in line with standard US-listed company practice. For the exact timing of upcoming earnings releases, check Kestra's investor relations page, as our data source does not cover specific future earnings dates.
Is KMTS a good stock to buy?
The UQS Score rates KMTS as Poor overall, driven by Weak Quality and Moat pillars alongside an Elevated Valuation. The Growth pillar is rated Good, which is a positive signal, but the combination of limited competitive durability and a demanding valuation warrants careful consideration. View the full pillar breakdown on UQS Pro for a complete picture.
Is KMTS overvalued?
The UQS Valuation pillar for KMTS is rated Elevated, suggesting the stock is priced above what current fundamentals alone would justify. This typically means the market is pricing in strong future growth. Given the Weak Quality and Moat scores, that premium carries meaningful execution risk.
How does KMTS compare to its competitors?
Kestra occupies a niche in wearable cardiac protection that differs from peers like AtriCure, which focuses on surgical ablation, or NovoCure, which targets oncology. While Kestra's growth trajectory is a relative positive, its Weak Moat suggests it has not yet established the durable competitive advantages seen in more mature medical device companies.
What is KMTS's market cap bracket?
KMTS is classified as a small-cap stock. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to large- or mega-cap peers, but may also offer greater growth potential if the company successfully scales its platform.
Who founded Kestra Medical Technologies?
Kestra Medical Technologies was founded in 2014. For detailed information on the founding team and leadership history, the company's official website and public filings are the most reliable sources.
Is KMTS a long-term quality investment?
As a long-term quality indicator, the UQS Score rates KMTS as Poor. The Weak Quality and Moat pillars suggest the business has not yet built the durable fundamentals typically associated with long-term compounders. The Good Growth pillar offers some encouragement, but sustained improvement across multiple pillars would be needed to change that overall assessment.
What is the main competitive advantage of Kestra Medical Technologies?
Kestra's differentiation centers on its integrated Cardiac Recovery System — combining a wearable defibrillator with digital health tools and patient support services in a single platform. However, the UQS Moat pillar is rated Weak, indicating that this integration has not yet translated into a clearly defensible competitive position relative to the broader medical device landscape.
What sector does KMTS belong to?
KMTS operates in the Healthcare sector, specifically within the medical device and digital health subsegment. It focuses on cardiovascular disease management through wearable therapeutic and monitoring technologies. You can explore other [healthcare sector stocks](/sector/healthcare) rated by UQS Score for broader context.
Unlock Full KMTS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores across all five UQS pillars
- ✓Access complete financial metrics and trend data
- ✓Compare KMTS against sector peers side by side
- ✓See the full valuation and risk breakdown
- ✓Get the complete analyst-style quality profile
Pro Analysis
KMTS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 27.0 | 3.3 | 23.0 | 61.5 | 54.2 | 0.0 | +3.4 |
| May 8, 2026 | 23.6 | 0.0 | 23.0 | 61.5 | 36.9 | 0.0 | -3.4 |
| Apr 22, 2026 | 27.0 | 3.3 | 23.0 | 61.5 | 54.2 | 0.0 | -3.1 |
| Apr 2, 2026 | 30.1 | 3.3 | 23.0 | 76.9 | 54.2 | 0.0 | — |
KMTS — Pillar Breakdown
Quality
— 3.3/100 (25%)Kestra Medical Technologies, Ltd. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 61.5/100 (20%)Kestra Medical Technologies, Ltd. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 54.2/100 (15%)Kestra Medical Technologies, Ltd. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Kestra Medical Technologies, Ltd. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 23/100 (25%)Kestra Medical Technologies, Ltd. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for KMTS.
Score Composition
Financial Data
More Stock Analysis
How is the KMTS UQS Score Calculated?
The UQS (Unified Quality Score) for Kestra Medical Technologies, Ltd. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Kestra Medical Technologies, Ltd.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Kestra Medical Technologies, Ltd. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.